Allopurinol is widely prescribed for primary and secondary hyperuricae
mia, and cutaneous adverse reactions are seen in 0.8-2.1% of recipient
s.1,2 The majority of these are mild and include pruritus, diffuse or
maculo-papular erythema, urticaria and ichthyosis.3 More severe reacti
ons are well recognized and include exfoliative dermatitis, toxic epid
ermal necrolysis and a generalized hypersensitivity syndrome.3-5 The l
atter typically comprises fever, rash, hepatic and renal dysfunction a
nd eosinophil leucocytosis.5 The occurrence of toxic pustuloderma due
to allopurinol, confirmed by re-challenge, is reported.